Pacific Biosciences of California, Inc.
NMS: PACBLive Quote
📈 ZcoreAI Score
Our AI model analyzes Pacific Biosciences of California, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PACB Z-Score →About Pacific Biosciences of California, Inc.
Healthcare
Medical Devices
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
📊 Fundamental Analysis
Pacific Biosciences of California, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 13.8% revenue growth, which is above average for the Healthcare sector.
Return on Equity (ROE) is -213.5%, which indicates that capital utilization is currently under pressure.
At a current price of $1.34, PACB currently sits at the 26th percentile of its 52-week range (Range: $0.85 - $2.73).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$404.68M
Trailing P/E
--
Forward P/E
-3.25
Beta (5Y)
2.33
52W High
$2.73
52W Low
$0.85
Avg Volume
6.66M
Day High
Day Low